- Home
- ACHC vs VERA Comparison
ACHC vs VERA Comparison
Compare ACHC & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHC
- VERA
- Stock Information
- Founded
- ACHC 2005
- VERA 2016
- Country
- ACHC United States
- VERA United States
- Employees
- ACHC N/A
- VERA N/A
- Industry
- ACHC Medical Specialities
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- ACHC Health Care
- VERA Health Care
- Exchange
- ACHC Nasdaq
- VERA Nasdaq
- Market Cap
- ACHC 1.7B
- VERA 1.4B
- IPO Year
- ACHC N/A
- VERA 2021
- Fundamental
- Price
- ACHC $21.92
- VERA $24.54
- Analyst Decision
- ACHC Buy
- VERA Buy
- Analyst Count
- ACHC 11
- VERA 8
- Target Price
- ACHC $41.23
- VERA $64.29
- AVG Volume (30 Days)
- ACHC 2.4M
- VERA 1.8M
- Earning Date
- ACHC 10-29-2025
- VERA 11-06-2025
- Dividend Yield
- ACHC N/A
- VERA N/A
- EPS Growth
- ACHC N/A
- VERA N/A
- EPS
- ACHC 1.52
- VERA N/A
- Revenue
- ACHC $3,229,609,000.00
- VERA N/A
- Revenue This Year
- ACHC $7.45
- VERA N/A
- Revenue Next Year
- ACHC $7.29
- VERA N/A
- P/E Ratio
- ACHC $14.38
- VERA N/A
- Revenue Growth
- ACHC 5.64
- VERA N/A
- 52 Week Low
- ACHC $17.13
- VERA $18.53
- 52 Week High
- ACHC $79.79
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- ACHC 49.13
- VERA 58.83
- Support Level
- ACHC $21.13
- VERA $22.72
- Resistance Level
- ACHC $24.42
- VERA $25.29
- Average True Range (ATR)
- ACHC 1.03
- VERA 1.20
- MACD
- ACHC -0.14
- VERA 0.13
- Stochastic Oscillator
- ACHC 28.77
- VERA 81.66
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.